BACKGROUND: Glutathione-dependent catalysis is a metabolic adaptation to chemical
challenges encountered by all life forms. In the course of evolution, nature optimized …

Methylene blue (MB), the first synthetic drug, has a 120-year-long history of diverse
applications, both in medical treatments and as a staining reagent. In recent years there was …

Experimenta naturae, like the glucose-6-phosphate dehydrogenase deficiency, indicate that
malaria parasites are highly susceptible to alterations in the redox equilibrium. This offers a …

The malaria parasite Plasmodium falciparum is highly adapted to cope with the oxidative
stress to which it is exposed during the erythrocytic stages of its life cycle. This includes the …

Methylene blue has intrinsic antimalarial activity and it can act as a chloroquine sensitizer. In
addition, methylene blue must be considered for preventing methemoglobinemia, a serious …

Parasitic diseases such as sleeping sickness, Chagas' heart disease, and malaria are major
health problems in poverty‐stricken areas. Antiparasitic drugs that are not only active but …

BACKGROUND: The tripeptide γ-glutamylcysteinylglycine or glutathione (GSH) has
demonstrated protective abilities against the detrimental effects of oxidative stress within the …

The flavoprotein disulfide reductases represent a family of enzymes that show high
sequence and structural homology. They catalyze the pyridine-nucleotide-dependent …

Background Methylene blue (MB) was the first synthetic antimalarial to be discovered and
was used during the late 19th and early 20th centuries against all types of malaria. MB has …

The review considers redox enzymes of Plasmodium spp., Trypanosomatida, Trichomonas,
Entamoeba and Giardia, with special emphasis on their potential use as targets for drug …